Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

First Report

Vibegron Proves Effective as Oral Therapy for Patients With Overactive Bladder
Vibegron Proves Effective as Oral Therapy for Patients With Overactive Bladder
First Report
Vibegron Proves Effective as Oral Therapy for Patients With Overactive Bladder
04/12/2021

Edan Stanley

Edan Stanley
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with...
04/12/2021
First Report Managed Care

Advertisement

Dupilumab Associated With Reduced Severe Asthma Exacerbation Rates Compared to Other Biologics
Per the results of an indirect treatment comparison, researchers found that dupilumab is associated with lower severe asthma exacerbation rates than patients treated with anti-IL-5s and o...
Early Real-World Data Shows Increased Patient Satisfaction, Demonstrates Effectiveness for AD Therapy
“While this dataset is still maturing, in this as-observed interim analysis of a real-world study, dupilumab demonstrated early and sustained improvement in AD flares, symptoms, and disea...
First Report
HEOR: Examining the Effectiveness, Costs of Various DLBCL Treatments
10/23/2020

Edan Stanley

Edan Stanley
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, according to the Lymphoma Research Foundation, and worldwide, accounting for about 22% of newly diagnosed cases of B-cell NHL in...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, according to the Lymphoma Research Foundation, and worldwide, accounting for about 22% of newly diagnosed cases of B-cell NHL in...
Diffuse large B-cell lymphoma...
10/23/2020
First Report Managed Care

Advertisement

Measuring Real-World Effectiveness of Dupilumab Using IGA Scores to Reduce Symptom Severity
A recent study shows successful reduction of signs, symptoms, and severity of atopic dermatitis based on real-world patient data.
First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020

Edan Stanley

Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
First Report
Decreased Medication, Utilization Costs Identified With Emicizumab-kxwh Therapy for Hemophilia
08/31/2020

Edan Stanley

Edan Stanley
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was...
08/31/2020
First Report Managed Care

Advertisement

High Persistence Examined With Dupilumab Among Adults With Atopic Dermatitis
Recent data showing high persistence rates for dupilumab therapy in patients with atopic dermatitis suggest that the treatment is well-tolerated and effective.
Decreased Medication, Utilization Costs Identified With Emicizumab-kxwh Therapy for Hemophilia
“In this analysis, emicizumab-kxwh therapy was associated with a decrease in the cost of HEM medications and cost and utilization of medical services,” explained researchers.

Advertisement

Advertisement

Advertisement

FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

What's Trending?

Commentary
The Role of JAK Inhibitors in the Treatment of Autoimmune and Autoinflammatory Diseases
12/14/2023
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus...
12/14/2023
First Report Managed Care
News
U.S. Lawmakers Will Not Tackle Healthcare This Year, Ryan Says: Reuters Interview
10/27/2017
House of Representatives Speaker Paul Ryan has announced that republican lawmakers will not take up a bipartisan plan to stabilize ACA insurance markets or try again to repeal and replace the law this year. 
House of Representatives Speaker Paul Ryan has announced that republican lawmakers will not take up a bipartisan plan to stabilize ACA insurance markets or try again to repeal and replace the law this year. 
House of Representatives Speaker...
10/27/2017
First Report Managed Care
News
Tick Tock: Medicare Payment Cuts for Docs Due to Start Monday
03/01/2010
03/01/2010
First Report Managed Care
Screening for Abdominal Aortic Aneurysm Urged for Older Male Smokers
08/18/2014

Eileen Koutnik-Fotopoulos

Eileen Koutnik-Fotopoulos
Abdominal aortic aneurysm (AAA), a risk factor for smokers, affects an estimated 3.9% to 7.2% of men and 1% to 1.3% of women ≥50 years of age. In an update to the 2005 recommendation on AAA screening, the United States Preventive Services...
Abdominal aortic aneurysm (AAA), a risk factor for smokers, affects an estimated 3.9% to 7.2% of men and 1% to 1.3% of women ≥50 years of age. In an update to the 2005 recommendation on AAA screening, the United States Preventive Services...
Abdominal aortic aneurysm (AAA),...
08/18/2014
First Report Managed Care
News
Valeant Approaches Meda About a Potential Deal
07/27/2011
07/27/2011
First Report Managed Care

Video Insights

Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Videos
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
09/25/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
09/25/2024
First Report Managed Care
Title Card
Videos
Addressing the Root Cause of a Common Ocular Condition: A Virtual Roundtable
09/04/2024
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on...
09/04/2024
First Report Managed Care
Jordan Bazinsky
Videos
Addressing Health Disparities and Promoting Equity: The Role of Advanced Imaging Solutions
08/15/2024
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky...
08/15/2024
First Report Managed Care
Farrukh Awan, MD
Videos
Promising Therapies and Clinical Trials for Chronic Lymphocytic Leukemia
08/14/2024
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights...
08/14/2024
Journal of Clinical Pathways
Hayward
Videos
Evolving Health Care Contact Centers Into Drivers of Value-Based Care
07/31/2024
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact...
07/31/2024
First Report Managed Care
Lucille Accetta Headshot
Videos
Enhancing Patient Medication Adherence: Insights and Strategies From Asembia 2024
06/11/2024
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health...
06/11/2024
First Report Managed Care
Melissa Andel, Principal, CommonHealth Solutions, LLC
Videos
Navigating the Impact of the Inflation Reduction Act: Implications for Payers, Patients, and Manufacturers
05/24/2024
Melissa Andel, Principal, CommonHealth Solutions, LLC
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the...
05/24/2024
First Report Managed Care
Joe DePinto Headshot
Videos
Navigating Payment Models in the CGT Landscape: Insights and Innovations
05/21/2024
Joe DePinto, Head of Cell, Gene, and Advanced Therapies, McKesson
An expert discusses the evolution and challenges of payment models in the cell and gene therapy (CGT) space reviewed during his session at Asembia 2024.
An expert discusses the evolution and challenges of payment models in the cell and gene therapy (CGT) space reviewed during his session at Asembia 2024.
An expert discusses the...
05/21/2024
First Report Managed Care
Jennifer L. Mathieu Senior Vice President, Professional and Government Affairs at AMCP
Videos
Unlocking the Future of Managed Care Pharmacy: A Deep Dive into Federal Legislation and Regulations
05/15/2024
Jennifer L. Mathieu Senior Vice President, Professional and Government Affairs, AMCP
Learn about developments in federal legislation and regulations within the pharmacy landscape shaping the future of managed care in an interview with a session presenter from AMCP 2024.
Learn about developments in federal legislation and regulations within the pharmacy landscape shaping the future of managed care in an interview with a session presenter from AMCP 2024.
Learn about developments in...
05/15/2024
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use